Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mixed WTO ruling on generic drug development.

R Elliott1

  • 1relliott@netrover.com

Canadian HIV-AIDS Policy & Law Newsletter
|February 9, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cross validation of pharmacokinetic bioanalytical methods: Experimental and statistical design.

Journal of pharmaceutical and biomedical analysis·2024
Same author

Do people recover from the impact of COVID-19 social isolation? Social connectivity and negative affective bias.

Psychological medicine·2024
Same author

Profiles of objective and subjective cognitive function in Post-COVID Syndrome, COVID-19 recovered, and COVID-19 naïve individuals.

Scientific reports·2024
Same author

Correction to: Building on existing tools to improve chronic disease prevention and screening in public health: a cluster randomized trial.

BMC public health·2021
Same author

Building on existing tools to improve chronic disease prevention and screening in public health: a cluster randomized trial.

BMC public health·2021
Same author

Corrigendum to 'Associations between Facets and Aspects of Big Five Personality and Affective Disorders: Systematic Review and Best Evidence Synthesis' [Journal of Affective Disorders Volume 288 (2021), pages 175-188].

Journal of affective disorders·2021

The World Trade Organization ruled Canada can allow generic drug development before patent expiry, but not stockpiling. This impacts global pharmaceutical markets and drug accessibility.

Area of Science:

  • Intellectual Property Law
  • Pharmaceutical Policy
  • International Trade Law

Background:

  • The World Trade Organization (WTO) reviewed Canada's patent law regarding pharmaceutical products.
  • Canadian law permits generic drug manufacturers to develop versions of patented drugs before patent expiration.
  • This provision aims to reduce delays in the availability of more affordable generic medications.

Discussion:

  • The WTO's decision impacts market exclusivity for pharmaceutical companies.
  • It addresses the balance between patent holder rights and public access to medicines.
  • The ruling highlights international trade agreement compliance in patent law.

Key Insights:

  • WTO upheld Canada's provision allowing pre-patent expiry generic drug development.

Related Experiment Videos

  • WTO ruled Canada's allowance of generic drug stockpiling violates international agreements.
  • The decision affects pharmaceutical market dynamics and drug pricing globally.

    • Outlook:

    • Potential for harmonization of patent laws across WTO member countries.
    • Implications for future trade disputes concerning intellectual property and generic medicines.
    • Continued debate on balancing innovation incentives with affordable healthcare access.